Secondary injury and inflammation after intracerebral haemorrhage : a systematic review and meta-analysis of molecular markers in patient brain tissue
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ..
BACKGROUND: Inflammatory responses to intracerebral haemorrhage (ICH) are potential therapeutic targets. We aimed to quantify molecular markers of inflammation in human brain tissue after ICH compared with controls using meta-analysis.
METHODS: We searched OVID MEDLINE (1946-) and Embase (1974-) in June 2020 for studies that reported any measure of a molecular marker of inflammation in brain tissue from five or more adults after ICH. We assessed risk of bias using a modified Newcastle-Ottawa Scale (mNOS; mNOS score 0-9; 9 indicates low bias), extracted aggregate data, and used random effects meta-analysis to pool associations of molecules where more than two independent case-control studies reported the same outcome and Gene Ontology enrichment analysis to identify over-represented biological processes in pooled sets of differentially expressed molecules (International Prospective Register of Systematic Reviews ID: CRD42018110204).
RESULTS: Of 7501 studies identified, 44 were included: 6 were case series and 38 were case-control studies (median mNOS score 4, IQR 3-5). We extracted data from 21 491 analyses of 20 951 molecules reported by 38 case-control studies. Only one molecule (interleukin-1β protein) was quantified in three case-control studies (127 ICH cases vs 41 ICH-free controls), which found increased abundance of interleukin-1β protein after ICH (corrected standardised mean difference 1.74, 95% CI 0.28 to 3.21, p=0.036, I2=46%). Processes associated with interleukin-1β signalling were enriched in sets of molecules that were more abundant after ICH.
CONCLUSION: Interleukin-1β abundance is increased after ICH, but analyses of other inflammatory molecules after ICH lack replication. Interleukin-1β pathway modulators may optimise inflammatory responses to ICH and merit testing in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Journal of neurology, neurosurgery, and psychiatry - 93(2022), 2 vom: 01. Feb., Seite 126-132 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loan, James Jm [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 16.02.2022 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/jnnp-2021-327098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329071173 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329071173 | ||
| 003 | DE-627 | ||
| 005 | 20240210232356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jnnp-2021-327098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM329071173 | ||
| 035 | |a (NLM)34362854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loan, James Jm |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secondary injury and inflammation after intracerebral haemorrhage |b a systematic review and meta-analysis of molecular markers in patient brain tissue |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2022 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a BACKGROUND: Inflammatory responses to intracerebral haemorrhage (ICH) are potential therapeutic targets. We aimed to quantify molecular markers of inflammation in human brain tissue after ICH compared with controls using meta-analysis | ||
| 520 | |a METHODS: We searched OVID MEDLINE (1946-) and Embase (1974-) in June 2020 for studies that reported any measure of a molecular marker of inflammation in brain tissue from five or more adults after ICH. We assessed risk of bias using a modified Newcastle-Ottawa Scale (mNOS; mNOS score 0-9; 9 indicates low bias), extracted aggregate data, and used random effects meta-analysis to pool associations of molecules where more than two independent case-control studies reported the same outcome and Gene Ontology enrichment analysis to identify over-represented biological processes in pooled sets of differentially expressed molecules (International Prospective Register of Systematic Reviews ID: CRD42018110204) | ||
| 520 | |a RESULTS: Of 7501 studies identified, 44 were included: 6 were case series and 38 were case-control studies (median mNOS score 4, IQR 3-5). We extracted data from 21 491 analyses of 20 951 molecules reported by 38 case-control studies. Only one molecule (interleukin-1β protein) was quantified in three case-control studies (127 ICH cases vs 41 ICH-free controls), which found increased abundance of interleukin-1β protein after ICH (corrected standardised mean difference 1.74, 95% CI 0.28 to 3.21, p=0.036, I2=46%). Processes associated with interleukin-1β signalling were enriched in sets of molecules that were more abundant after ICH | ||
| 520 | |a CONCLUSION: Interleukin-1β abundance is increased after ICH, but analyses of other inflammatory molecules after ICH lack replication. Interleukin-1β pathway modulators may optimise inflammatory responses to ICH and merit testing in clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a neuropathology | |
| 650 | 4 | |a stroke | |
| 650 | 4 | |a systematic reviews | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Kirby, Caoimhe |e verfasserin |4 aut | |
| 700 | 1 | |a Emelianova, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Dando, Owen R |e verfasserin |4 aut | |
| 700 | 1 | |a Poon, Michael Tc |e verfasserin |4 aut | |
| 700 | 1 | |a Pimenova, Leisan |e verfasserin |4 aut | |
| 700 | 1 | |a Hardingham, Giles E |e verfasserin |4 aut | |
| 700 | 1 | |a McColl, Barry W |e verfasserin |4 aut | |
| 700 | 1 | |a Klijn, Catharina Jm |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Shahi Salman, Rustam |e verfasserin |4 aut | |
| 700 | 1 | |a Schreuder, Floris Hbm |e verfasserin |4 aut | |
| 700 | 1 | |a Samarasekera, Neshika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology, neurosurgery, and psychiatry |d 1944 |g 93(2022), 2 vom: 01. Feb., Seite 126-132 |w (DE-627)NLM00005190X |x 1468-330X |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:126-132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jnnp-2021-327098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2022 |e 2 |b 01 |c 02 |h 126-132 | ||